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Abstract
Background: The main clinical forms of tegumentary leishmaniasis are cutaneous leishmaniasis (CL) and
mucosal leishmaniasis (ML). L.braziliensis infection is characterized by an exaggerated production of IFN-gamma and
TNF-alpha, cytokines involved in parasite destruction, but also in the pathology. Maintenance of an antigen-specific
immune response may be important for resistance to re-infection and will contribute for vaccine development.
In the present work we investigated the immune response in CL and ML cured individuals.
Methods: Participants in the present study included 20 CL and 20 ML patients, who were evaluated prior to, as
well as 2 to 15 years after therapy. IFN-gamma, IL-2 and TNF-alpha production were determined by ELISA in
supernatants of mononuclear cells stimulated with soluble L.braziliensis antigen (SLA). The frequency of memory
CD4+ T cell populations was determined by FACS.
Results: Here we show that the majority of CL and ML patients did not produce in vitro IFN-gamma in response
to SLA after cure. In the cured individuals who responded to SLA, effector memory (CD45RA-CCR7-) CD4+ T cells
were the ones producing IFN-gamma. Because a large percent of CL and ML cured patients lost SLA-induced
IFN-gamma production in peripheral blood, we performed Leishmania skin test (LST). A positive LST was found in
87.5% and 100% of CL and ML cured individuals, respectively, who did not produce IFN-gamma or IL-2 in vitro.
Conclusion: This study shows that in spite of losing in vitro antigen-specific response to Leishmania, cured CL and ML
subjects retain the ability to respond to SLA in vivo. These findings indicate that LST, rather than IFN-gamma production,
may be a better assessment of lasting immunity to leishmaniasis in human studies, and thus a better tool for assessing
immunization after vaccine. Furthermore, in cured individuals which maintains Leishmania-specific IFN-gamma
production, effector memory CD4+ T cells were the main source of this cytokine.
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Background
Control of Leishmania infection relies on cell-mediated
immune response, as IFN-gamma induced activation of
macrophages is known to be the main mechanism of
parasite destruction within these cells. Peripheral blood
mononuclear cells (PBMC) from patients with cutaneous
leishmaniasis (CL) and mucosal leishmaniasis (ML),
due to L. braziliensis infection, secrete high levels of
TNF-alpha and IFN-gamma that contributes for the
control of parasite multiplication and dissemination
[1]. However, the inflammatory response observed in
these patients is not well regulated and leads to tissue
damage and ulcer formation [1,2]. In L. braziliensis-
infected subjects CD4+ T cells are the main source of
IFN-gamma, which is why these cells are the key
players in host defense against Leishmania infection
[3,4]. Moreover, the frequency of memory CD4+ T cells
in CL patients is higher than in uninfected controls [3].
Immunological memory is the ability of the immune
system to respond fast and better upon antigen exposure
than the first exposure to the same antigen. Memory T
cells can be maintained long-term, exhibit increased
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resistant to apoptosis and play a key role in resistance
to reinfection and vaccine [5]. The phenotypical and
functional characterization of memory T cells, revealed
that memory CD4+ T cells constitute a heterogeneous
population: CD45RA-CCR7+ (central memory) and CD
45RA-CCR7- (effector memory). While effector memory
CD4+ T cells can be found in blood and rapidly respond
with IFN-gamma production upon re-infection, the
central memory ones circulates among lymphoid organs
[6], although retains the ability of down-regulate lymph
node migration markers expression and become effector
cells upon IL-12 production [6,7]. The few studies
aimed to understand the dynamics of memory CD4+ T
cell populations in mouse model of leishmaniasis showed
that early following infection of C57BL/6 mouse, both
central and effector memory CD4+ T cells are generated
[8,9]. In these mice, Leishmania parasites persists for long
term and both effector and central memory population
long live and mediate protection during re-infection.
Differently, a transgenic L. major strain, which infected
but not survived for a long term in mice, resulted in
sterile cure and loss of effector memory CD4+ T cell
population, but retained central memory CD4+ T cells.
In such case, even in the absence of parasites central
memory T cells were able to mediate protection [8,9].
These data suggest that persistence of Leishmania para-
sites is not necessary for the survival of central memory
CD4+ T cells and consequently protection to re-infection.
The natural history of human tegumentary leishmaniasis
indicates that after lesion resolution individuals acquire
long lasting immunity and re-infection with L. braziliensis
only occurs in the minority of the subjects, as only
5.2% of cured leishmaniasis patients will develop new
CL lesions [10]. Indeed, in the Middle East, the practice
of immunizing people with a low inoculum of L. major,
known as “leishmanization”, results in up to 80% pro-
tection [11,12].
In the present work we investigated the immune re-
sponse in CL and ML cured individuals. We found that
a sub-group of cured CL and ML individuals have lost
circulating Leishmania specific Th1 cells, here determined
by the absence of SLA-induced IL-2 and IFN-gamma
production. Interestingly, despite losing circulating
Leishmania reactive Th1 cells, a majority of these indi-
viduals retained the ability to respond to Leishmania
antigens in vivo as they remain delayed type hypersensitivity
(DTH) positive. Moreover, in these cured subjects who
retained the ability to produce IFN-gamma, the source
of this cytokine was effector memory CD4+ T cells.
Methods
Patients
Twenty CL and twenty ML patients were studied during
active disease and 2 to 15 years post therapy. All
individuals were recruited at the health post of Corte de
Pedra, a region of L. braziliensis transmission in southeast
of Bahia state, Brazil. All patients were volunteers,
informed consent was obtained from all individuals
prior to participation in the study, and the research
project was approved by the ethical committee of the
Federal University of Bahia. The criteria used for the
diagnosis of CL and ML were the presence of a typical
ulcerated cutaneous or mucosal lesions, associated
with a positive DTH test and a positive PCR for L.
braziliensis. All individuals were treated with pentavalent
antimony (20 mg/kg/day) for 20 days for CL and 30 days
for ML. The blood for immunological evaluation was
drawn before and up to 15 years after therapy, and in
both cases it preceded the Leishmania skin test (LST).
Antigen and intradermal skin test
Soluble Leishmania antigen (SLA) was prepared as
previously described [13], tested for endotoxin using
the limulus amebocyte lysate test and used at a concen-
tration of 5 μg/ml. For intradermal skin test, 0,1 ml of
L. braziliensis antigen was inoculated in the forearm of
individuals and induration was determined 48 hours
post inoculation. A positive LST was considered when
the induration was grater than 5 mm. The antigen used
for LST was previously tested in healthy subjects and
no induration was observed after 48 hours.
PBMC culture and ELISA for cytokines
PBMC were isolated from heparin-treated venous blood
by ficoll-hypaque gradient centrifugation. After washing
three times in 0.9% NaCl, cells were re-suspended in
RPMI 1640 culture medium (GIBCO BRL, Grand Island,
NY) supplemented with 10% human AB serum, 100 IU/
ml of penicillin and 100 μg/ml of streptomycin. Cells
were adjusted to 3×106 cells/ml, put in 24-well plates
and stimulated with SLA (5 μg/ml). After incubation
for 72 hours at 37°C and 5% CO2, supernatants were
collected and stored at –20°C. The levels of IFN-gamma,
TNF-alpha, IL-2 and IL-10 were measured by ELISA
(R&D Systems, Minneapolis, MN) sandwich method and
the results expressed as pg/ml.
Flow cytometry
Flow cytometry was performed as previously described
[14], Briefly, PBMC (5×105) were stained with fluoro-
chrome-conjugated antibodies for surface markers CD4,
CD45RA, CCR7 (e-Bioscience) and fixed by using 2%
formaldehyde. For intracellular staining, cells were
stimulated with SLA (5 μg/ml) and cultured for 12 hours,
plus 8 hours in presence 10 μg/ml of Brefeldin A (Sigma).
Cells were than fixed as above, permeabilized with a
solution of 0.5% of saponin, and stained for 30 min at
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4°C using fluorochrome-conjugated antibodies against
IFN-gamma or isotype control antibodies.
Samples were processed on a FACSCantoII flow cyt-
ometer (BD Pharmingen), and analysis was performed
using FlowJo software (Tree Star). Analysis gates were
based live cells, CD4+ T cells and CD45RA negative
cells, as indicated in the figure legends.
Statistical analysis
The Wilcoxon non-parametric paired test was used to
assess differences between cytokines levels in the same
subjects. Analyses were conducted using Prism (GraphPad
Software Inc., San Diego, CA, USA); a P value of <0.05
was considered significant.
Results
Demographic and clinical data in CL and CM
cured individuals
The age, gender, skin test area (mm2), number of series
of pentavalent antimony, stage of mucosal disease and
time between evaluations are shown in Table 1. The mean
age was 23 ± 10 years for cutaneous group and 37 ±
12 years for mucosal patients. Overall, there was a
predominance of male individuals (65% and 75%) in
CL and ML respectively groups. The median of skin
test area was 187 mm2 (80 – 625) for CL patients and
300 mm2 (56 – 1722) for ML patients. While most
individuals with CL (85%) were treated with one serie
of pentavalent antimony, 50% of individuals with ML
required more than one series. The majority of ML
patients were in stage II (superficial ulceration) or stage
III (deep ulceration) of mucosal disease [15]. The interval
between the evaluations in months was 94 (38 – 161)
and 106 (28 – 184) for CL and ML respectively groups.
Loss of SLA-induced IFN-gamma and TNF-alpha production
in CL and ML cured individuals
CL and ML patients due to L. braziliensis infection
mount a strong inflammatory response with high levels
of IFN-gamma and TNF-alpha. The levels of Leishmania-
specific IFN-gamma produced by PBMCs from CL and
ML patients significantly decreased after therapy from
1355 pg/ml (282 – 9700) to 78 pg/ml (0 – 2228) and
4759 pg/ml (247 – 41860) to 28 pg/ml (0 – 2769), respect-
ively. Moreover, in 10 (50%) and 11 (55%) of CL and ML
cured individuals, respectively, IFN-gamma production
was not detected. TNF-alpha levels in CL and ML dropped
from 656 pg/ml (0 – 2280) to 24 pg/ml (0 – 847) and
1533 pg/ml (54 – 3895) to 57 pg/ml (0 – 993) respectively
(Figure 1). Although in the majority of patients a
marked decrease in both IFN-gamma and TNF-alpha
was observed, in two patients with CL there was an
increase in IFN-gamma after therapy and in one of
them TNF-alpha level did not change after therapy.
The therapeutic response to antimony in these two
cases was similar to the others CL patients. Both of
them received only one course of antimony, were cured
with less than 90 days after initiation of therapy and
the evaluation after therapy was performed 12 years
after cure. One of these patients presented the largest
cutaneous ulcer. Both patients remained free of disease
after 12 years of follow up.
As the time between the evaluations ranged from 28
to 184 months, we determined if the decrease or absence
of IFN-gamma production was related to the duration
of time between the evaluations. We compared the
immune response in CL and ML patients that were
evaluated after therapy with 5 years or less, with the
group that was evaluated after more than 6 years (Table 2).
A significant decrease in IFN-gamma production was
observed after therapy in CL subjects that were evaluated
with 5 or less years after cure (P = 0.03) or more than
6 years (P = 0.01). A significant reduction in IFN-gamma
production in ML patients was also detected in those
who were evaluated with or less than 5 years after cure
(p = 0.003) or and in ML patients evaluated 6 years
after cure (p = 0.001) in comparison with IFN-gamma
levels before therapy. In addition to the decreasing or
absence of IFN-gamma production, IL-10 levels were
undetectable in supernatants of PBMC culture stimulated
with Leishmania antigen (data not shown). IL-2 produc-
tion was observed 13 (32.5%) of 40 cured tegumentary
leishmaniasis patients (data not shown).There was an
association between IL-2 and IFN-gamma production
as of the 13 cases who had IL-2 detectable 11 (84.6%)
Table 1 Demographic and clinical features of CL and ML
cured individuals
Cutaneous
leishmaniasis (n = 20)
Mucosal leishmaniasis
(n = 20)
Age 23 (13–48) 37 (12–58)
Gender (male) 13 (65%) 15 (75%)




1 17 (85%) 10 (50%)
2 3 (15%) 9 (45%)
3 - 1 (5%)
Stage of
mucosal disease
II - 8 (40%)
III - 8 (40%)
≥ IV - 4 (20%)
Months between
evaluations
94 (38–161) 106 (28–184)
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Figure 1 IFN-gamma and TNF-alpha production in CL and ML patients before and after treatment. PBMC from patients with CL (A and B)
and ML (C and D) were obtained and stimulated with SLA (5 μg/ml) for 72 hours. IFN-gamma and TNF-alpha levels were determined on culture
supernatants by ELISA.
Table 2 IFN-γ production pre and post therapy in patients with cutaneous and mucosal leishmaniasis
Disease Time of evaluation
after therapy
IFN-gamma p
(Median and range) value
Pre therapy Post therapy
Cutaneous
Leishmaniasis ≤ 5 years 3608 pg/ml 34.5 pg/ml 0.0313
(N = 6) (288 – 9700 pg/ml) (0 - 2228 pg/ml)
Cutaneous
Leishmaniasis 6 to 13 years 1086 pg/ml 89.5 pg/ml 0.0107
(N = 14) (433 – 3873 pg/ml) (0 – 2152 pg/ml)
Mucosal
Leishmaniasis ≤ 5 years 4998 pg/ml 12 pg/ml 0.0039
(N = 9) (529 – 41860 pg/ml) (0 – 2769 pg/ml)
Mucosal
Leishmaniasis 6 to 15 years 4520 pg/ml 64 pg/ml 0.0010
(N = 11) (247 – 9660 pg/ml) (0 – 2712 pg/ml)
NOTE: Data are median. (range) of subjects. Statistics analysis was determined by Wilcoxon matched pairs test.
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also had IFN-gamma detected. Moreover IL-2 was not
produced subjects who did not produce IFN-γ.
Evidence of delayed type hypersensitivity (DTH) response
in cured CL and ML subjects
Although there is usually a good correlation between
DTH and T cells responses in vitro, there are evidences
of discordant results between in vivo and in vitro tests of
cell-mediated immune response [16,17]. To investigate if
individuals cured of CL and ML who did not produce
IFN-gamma and IL-2 had evidence of DTH to Leishmania
antigen, the LST was performed in cured CL and ML
subjects without evidence of in vitro IFN-gamma pro-
duction after stimulation with SLA. A positive DTH
was found in7/8 (87.5%) and 7/7 (100%) of CL and ML
cured individuals, respectively.
Effector memory CD4+ T cells are the main IFN-gamma
secreting cells in CL and ML cured individuals
The duration that the immunologic response to Leish
mania antigen remains after therapy may be an indicator
of memory duration after infection with Leishmania and
this information will be relevant in vaccine development
for leishmaniasis. Studies using experimental models
have shown that even after elimination of Leishmania
parasites from the host, central memory CD4+ T cells
confers protection to re-infection [8]. We assessed
memory CD4+ T cell populations in CL and ML cured
individuals (Figure 2A,B and C). There was no difference
in the percentage of CD4+ effector or central T cells
memory populations observed in CL and ML cured
patients (p = 0.1). Because the majority of memory T
cell populations in humans are not Leishmania-specific,
we decided to assess the SLA-induced IFN-gamma
production by memory T cell populations in CL and
ML cured individuals who remained with an immune
response as assessed by IFN-gamma production after
therapy. The CD4+ T cells are the main IFN-gamma
secreting population in those individuals who responded
to SLA (data not shown). Moreover, effector memory
(CD45RA- CCR7-) CD4+ T cells were the main source
of IFN-gamma after therapy in subjects whom remained
producing IFN-gamma after therapy (p = 0.01) (Figure 3).
Discussion
The systemic and tissue immunologic response in
patients with CL or ML due to L. braziliensis have been
well characterized and it has been shown that CD4+ T
cells are the main source of IFN-gamma and also an
important source of TNF-alpha during active disease
[3,4]. As only 5% of subjects cured of L. braziliensis
infection have a new episode of the disease [10] it is
likely that protective immunity is maintained long after
cure of CL and ML. However, very little is known about
memory T cells in human leishmaniasis. A few studies
have evaluated immunologic response by lymphocyte
proliferation and cytokine production in subjects cured
of CL and usually evidence of T cells response have
been documented after cure [18-20]. Here we show that
the majority of CL and ML cured patients not only
decrease IFN-gamma and TNF-alpha production after
cure, but also that in a large percentage of cured subjects
the IFN-gamma, TNF-alpha and IL-2 was not detected.
Several possibilities may explain the discordant results
regarding immunologic response after therapy of leish-
maniasis: 1) the kind of antigen used in the assay; 2) if
the same antigen was used before and after cure; 3) the
antimony dose used for treatment of active lesions; 4)
the healing time of the lesions; 5) if the evaluation pre
and post therapy was performed in the same subjects.
In some of these previous studies, killed or disrupted L.
braziliensis were used as source of antigen [18-20] and
in such case lymphocyte immune response can be
observed even in unexposed individuals. Similar levels
of IFN-gamma and lower levels of IL-4 and IL-10 were
observed in subjects cured of CL in comparison with
the concentration of these cytokines in patients with
active disease, but the evaluation after therapy was not
performed in same subjects [19]. Another study show
that in cured CL and ML subjects, IFN-gamma levels were
quite variable and in more than half of the patients studied
low levels of IFN-gamma were observed [20]. Indeed,
despite the recommended dose of pentavalent antimony
to treat CL is 20 mg/Kg/day for 20 days, lower dose of
intravenous antimony, different duration of treatment
and topical rather than intravenous antimony therapy
have been used for the treatment of leishmaniasis
[21,22]. The time between the initiation of the antimony
therapy and the clinical cure is also key in understand
the significance of the values obtained for immunological
tests after cure. It is known that the majority of patients
with CL will have a self-healing disease that is dependent
of the duration of the illness. If no information about
the time of cure is given, it cannot be ruled out that
cure may have occurred independent of the therapy. It
is known that individuals with self-healing CL remain
with a very strong lymphocyte proliferative response to
Leishmania antigens [23]. In the present study soluble
rather than disrupted L. braziliensis antigen was used,
the same dose of antimony was given to all patients, the
criteria of cure was standardized and the time between
the initiation of therapy and the cure was determined.
Therefore it is likely that the presence of one or more
of these factors may explain discordant results regard-
ing immunological response after cure of tegumentary
leishmaniasis.
As the majority of the cured CL and ML patients had
no evidence of IFN-gamma and IL-2 production, the
















Figure 2 Percentage of effector and central memory CD4+ T cell populations. A, gate strategy. B, representative plot showing CCR7-
(effector memory) or CCR7+ (central memory), in a ML cured individual and the isotype control antibodies. C, frequency of effector memory and
central memory in 7 cured subjects. PBMC were analyzed ex vivo gated on CD4+ CD45RA-.
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LST was performed in these cured subjects to evaluated
in vivo immune response to parasite antigen. As a good
correlation between in vitro immunological response and
the DTH reaction is usually observed, the documentation
that the LST was positive after therapy in subjects who
did not have evidence in vitro of T cell response was
unexpected. However, a discordance between in vivo
and in vitro immunological tests have been documented
in subjects with latent tuberculosis [16,17] and more
recently we also observed only a weak concordance
between the LST and IFN-gamma production to SLA in
household contacts of CL patients [24]. Several possibil-
ities may explain these discordant results such as presence
of soluble factors in patients with active disease that
may act in vivo, the nutritional status of the subjects
and sub-populations of memory T cells [25]. As in our
case subjects were disease free and well-nourished, it is
likely that the positive LST in the absence of immuno-
logical response in vitro was due to the lack of circulating
antigen-specific T cells. In such case as the antigen
injected intradermal remain for some period of time in
the tissue, there was enough time for memory cells
retained in lymph nodes or other tissues migrate to the
site of the antigen administration resulting in positive LST.
Our results pointed out that the effector memory
(CD45RA- CCR7-) CD4+ T cells were the main population
producing IFN-gamma in cured CL and ML individuals
who responded in vitro to SLA. Giving support to our
data, previous observation in mouse model of L. major
infection indicates that effector memory CD4+ T cells
are the main source of IFN-gamma [8]. Also, it was
shown that in subjects with history of CL caused by L.
major or L. tropica, effector memory CD4+ T cells were
the main source of IFN-gamma production [26].
According to the available data in the literature and
our current results demonstrating that, even losing
circulating Leishmania antigen-specific IFN-gamma
producers T cell populations, the majority of these
individuals do not develop disease. Thus, four main
hypothesis can be raised: 1) Individuals that lost circu-
lating IFN-gamma CD4+ T cells have cleared infection
and have not been re-infected. 2) Memory CD4+ T cells
are confined to lymph nodes rather than in peripheral
blood. 3) Memory CD4+ T cells are allocated in skin 4)
Resistance to leishmaniasis does not rely on memory
CD4+ T cells. All of four possibilities are difficult to be
addressed in human studies. However, the hypothesis
of memory CD4+ T cells be sequestrated in lymphoid
organs or in the skin was previously documented [27-29].
The observation of positive LST in the absence of
IFN-gamma producing T cells in response to Leishmania
antigens argue in favor of the presence of tissue-resident
memory T cell (TRM). Actually, it has been shown that
TRM may remain resident in the skin even the absence of
antigen stimulation and are able to mediate protection to
herpes simplex virus infection in C57BL/6 mice [28,29].
As all patients were cured remain question, why some
patients have ability to produce IFN-gamma and others
loose it. Persistence or not of the parasite after therapy
could influence presence or absence of IFN-gamma
production. Actually, there is evidence that Leishmania
may persist in the scars after cure. However, due to ethical
reasons biopsies were not performed after cure in this
study. Enhancement of IL-10, an important regulatory
cytokines has been observed after cure of CL [20].
Moreover, presence of IL-10-producing T cells in dermis
of chronic L. major-infected mice prevented protection
against challenge [30]. However, as assessed by ELISA,
we could not find IL-10 production in cured CL and ML
patients. Finally, it cannot be ruled out the hypothesis of
those cured individuals who maintained in vitro response
to Leishmania antigen is due to recent re-infection.
Conclusion
Our data pointed out that despite the majority of cured
CL and ML patients loose ability to produce cytokines
upon in vitro stimulation of PBMC with Leishmania
antigens, immunity to L.braziliensis infection last long.
In those individuals with evidence of in vitro immune
response effector memory CD4+ T cells were the IFN-
gamma producers. Moreover, our data argues in favor
that LST is an important test to assess immunity after
cure of leishmaniasis and should be used in addition to
in vitro tests to evaluate immune response to vaccines
in human studies.
Figure 3 IFN-gamma expression by effector and central
memory CD4+ T cell in cured ML subjects. Graph showing the
frequency of cells positive for IFN-gamma in the two populations
of memory CD4+ T cells with or without SLA stimulus from 7 cured
patients. The expression of IFN-gamma was determined by flow
cytometry. Cells were evaluated in the CD4+CD45RA- gate.
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